company background image
ORNBV logo

Orion Oyj HLSE:ORNBV Stock Report

Last Price

€58.90

Market Cap

€8.4b

7D

5.3%

1Y

56.6%

Updated

22 May, 2025

Data

Company Financials +

Orion Oyj

HLSE:ORNBV Stock Report

Market Cap: €8.4b

ORNBV Stock Overview

Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details

ORNBV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance6/6
Financial Health5/6
Dividends4/6

Rewards

Trading at 32.6% below our estimate of its fair value

Earnings are forecast to grow 9.03% per year

Earnings grew by 60.2% over the past year

Risk Analysis

Dividend of 2.78% is not well covered by free cash flows


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Orion Oyj Competitors

Price History & Performance

Summary of share price highs, lows and changes for Orion Oyj
Historical stock prices
Current Share Price€58.90
52 Week High€60.40
52 Week Low€36.15
Beta0.34
1 Month Change23.84%
3 Month Change12.32%
1 Year Change56.65%
3 Year Change55.04%
5 Year Change25.59%
Change since IPO323.74%

Recent News & Updates

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

May 13
Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Orion Oyj (HEL:ORNBV) Will Pay A Dividend Of €0.82

Apr 16
Orion Oyj (HEL:ORNBV) Will Pay A Dividend Of €0.82

Recent updates

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

May 13
Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Orion Oyj (HEL:ORNBV) Will Pay A Dividend Of €0.82

Apr 16
Orion Oyj (HEL:ORNBV) Will Pay A Dividend Of €0.82

If EPS Growth Is Important To You, Orion Oyj (HEL:ORNBV) Presents An Opportunity

Mar 31
If EPS Growth Is Important To You, Orion Oyj (HEL:ORNBV) Presents An Opportunity

Here's What Analysts Are Forecasting For Orion Oyj (HEL:ORNBV) After Its Yearly Results

Feb 28
Here's What Analysts Are Forecasting For Orion Oyj (HEL:ORNBV) After Its Yearly Results

Pinning Down Orion Oyj's (HEL:ORNBV) P/E Is Difficult Right Now

Jan 20
Pinning Down Orion Oyj's (HEL:ORNBV) P/E Is Difficult Right Now

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Nov 24
A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Impressive Earnings May Not Tell The Whole Story For Orion Oyj (HEL:ORNBV)

Nov 06
Impressive Earnings May Not Tell The Whole Story For Orion Oyj (HEL:ORNBV)

Orion Oyj's (HEL:ORNBV) Shareholders Might Be Looking For Exit

Sep 25
Orion Oyj's (HEL:ORNBV) Shareholders Might Be Looking For Exit

Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Sep 02
Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Orion Oyj Just Beat EPS By 13%: Here's What Analysts Think Will Happen Next

Aug 12
Orion Oyj Just Beat EPS By 13%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 42%?

Jul 14
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 42%?

Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon

Jun 17
Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon

Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly

May 27
Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly

Shareholder Returns

ORNBVFI PharmaceuticalsFI Market
7D5.3%4.3%2.1%
1Y56.6%-18.0%0.6%

Return vs Industry: ORNBV exceeded the Finnish Pharmaceuticals industry which returned -18% over the past year.

Return vs Market: ORNBV exceeded the Finnish Market which returned 0.6% over the past year.

Price Volatility

Is ORNBV's price volatile compared to industry and market?
ORNBV volatility
ORNBV Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement5.3%
10% most volatile stocks in FI Market8.8%
10% least volatile stocks in FI Market3.6%

Stable Share Price: ORNBV has not had significant price volatility in the past 3 months compared to the Finnish market.

Volatility Over Time: ORNBV's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19173,943Liisa Hurmewww.orionpharma.com

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Orion Oyj Fundamentals Summary

How do Orion Oyj's earnings and revenue compare to its market cap?
ORNBV fundamental statistics
Market cap€8.40b
Earnings (TTM)€347.40m
Revenue (TTM)€1.59b
23.9x
P/E Ratio
5.2x
P/S Ratio

Is ORNBV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORNBV income statement (TTM)
Revenue€1.59b
Cost of Revenue€610.90m
Gross Profit€977.60m
Other Expenses€630.20m
Earnings€347.40m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 18, 2025

Earnings per share (EPS)2.47
Gross Margin61.54%
Net Profit Margin21.87%
Debt/Equity Ratio30.1%

How did ORNBV perform over the long term?

See historical performance and comparison

Dividends

2.8%
Current Dividend Yield
66%
Payout Ratio

Does ORNBV pay a reliable dividends?

See ORNBV dividend history and benchmarks
When do you need to buy ORNBV by to receive an upcoming dividend?
Orion Oyj dividend dates
Ex Dividend DateOct 15 2025
Dividend Pay DateOct 23 2025
Days until Ex dividend145 days
Days until Dividend pay date153 days

Does ORNBV pay a reliable dividends?

See ORNBV dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 17:46
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Orion Oyj is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
Graham Glyn ParryBofA Global Research
Charlie HaywoodBofA Global Research